Sigilon Therapeutics, Inc.
SGTX · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $6 | $5 | $3 | $4 |
| % Growth | 21.4% | 83.7% | -37.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $5 | $3 | $4 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7 | $8 | $6 | $8 |
| G&A Expenses | $6 | $4 | $5 | $4 |
| SG&A Expenses | $6 | $4 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $12 | $10 | $13 |
| Operating Income | -$7 | -$7 | -$8 | -$8 |
| % Margin | -126% | -149.2% | -292.4% | -198.1% |
| Other Income/Exp. Net | -$0 | -$0 | $1 | -$0 |
| Pre-Tax Income | -$8 | -$7 | -$7 | -$9 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$8 | -$8 | -$6 | -$9 |
| % Margin | -127.2% | -154.6% | -213.3% | -209.8% |
| EPS | -0.23 | -0.23 | -0.17 | -0.28 |
| % Growth | 0% | -35.3% | 39.3% | – |
| EPS Diluted | -0.23 | -0.23 | -0.17 | -0.28 |
| Weighted Avg Shares Out | 32 | 32 | 32 | 32 |
| Weighted Avg Shares Out Dil | 32 | 32 | 32 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $1 | $2 | $1 |
| EBITDA | -$7 | -$6 | -$4 | -$8 |
| % Margin | -116.7% | -132.8% | -164.1% | -182.2% |